Avastin, Erbitux Prices Invite Price Controls, Former NCI Deputy Says In Editorial
This article was originally published in The Pink Sheet Daily
Executive Summary
The prices set by Genentech and Bristol-Myers Squibb for their recently launched colorectal cancer therapies are an invitation to impose price controls, former Memorial-Sloan Kettering Cancer Center Physician-in-Chief Robert Wittes, MD, wrote in an editorial published by the Washington Post June 15